Symbol="IKT"
AssetType="Common Stock"
Name="Inhibikase TherapeuticsÂ Inc"
Description="Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia."
CIK="1750149"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="15953000"
EBITDA="-18121884"
PERatio="None"
PEGRatio="None"
BookValue="4.892"
DividendPerShare="0"
DividendYield="0"
EPS="-3.39"
RevenuePerShareTTM="0.033"
ProfitMargin="0"
OperatingMarginTTM="-128.25"
ReturnOnAssetsTTM="-0.342"
ReturnOnEquityTTM="-0.603"
RevenueTTM="141930"
GrossProfitTTM="-8258499"
DilutedEPSTTM="-3.39"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.402"
AnalystTargetPrice="27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="219.63"
PriceToBookRatio="0.492"
EVToRevenue="2.748"
EVToEBITDA="0.733"
Beta="0.826"
num_52WeekHigh="7.26"
num_52WeekLow="2.64"
num_50DayMovingAverage="3.735"
num_200DayMovingAverage="3.983"
SharesOutstanding="5300000"
DividendDate="None"
ExDividendDate="None"
symbol="IKT"
open="2.80"
high="3.14"
low="2.80"
price="2.94"
volume="44431.00"
latest_trading_day="2023-07-11"
previous_close="2.95"
change="-0.01"
change_percent="-0.3390%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="63"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="37"
Volume_recent_avg="222088"
Change_recent_avg="0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-0.71"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="37"
Aroon_momentum_negative="63"
image_negative_thumbnail_id_1="490"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0115.jpeg"
image_negative_thumbnail_id_2="1139"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0172.jpeg"
image_neutral_thumbnail_id_1="521"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_neutral_thumbnail_id_2="587"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0012.jpeg"
image_positive_thumbnail_id_1="980"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0142.jpeg"
image_positive_thumbnail_id_2="982"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0144.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1191"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
